Bioactivity:

Ponatinib is an oral drug for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. It is a multi-targeted tyrosine kinase inhibitor. Ponatinib has been designed to be effective against these ty

CAS nr:

1114544-31-8

Purity:

98%

Molecular Weight:

569,03

SMILES:

O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(C#CC4=CN=C5C=CC=NN54)=C3.[H]Cl

Formula:

C29H28ClF3N6O

Pathway:

Target: